At a glance
- Originator Eli Lilly and Company
- Class Anti-ischaemics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Naphthalenes; Pyrans; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Metalloprotease inhibitors; Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic angiopathies; Ischaemic heart disorders; Rheumatic disorders
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 24 Oct 1996 Preclinical development for Ischaemic heart disorders in USA (Unknown route)
- 18 Sep 1996 LY 290181 failed to pass through 2-week toxicology studies